Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: Human studies

Keyphrases

• Human Studies 100%
• Non-alcoholic Fatty Liver Disease (NAFLD) 100%
• Liver Steatohepatitis 100%
• Lipid-lowering Agents 100%
• Nonalcoholic Steatohepatitis 58%
• Statins 16%
• Hepatic Steatosis 16%
• Lipid-lowering Treatment 16%
• High Risk 8%
• Alcohol 8%
• Randomized Controlled Study 8%
• Fibrosis 8%
• Online Database 8%
• Incidental 8%
• Hepatocellular Carcinoma 8%
• Developing World 8%
• Most Common Cause 8%
• Obesity Diabetes 8%
• Metabolic Syndrome Components 8%
• Cirrhosis 8%
• Chronic Liver Disease 8%
• Serum Liver Enzymes 8%
• Lifestyle Modification 8%
• Disease Foci 8%
• Asymptomatic Diseases 8%
• Fibrates 8%
• Abnormal Liver Tests 8%
• Risk for Cardiovascular Diseases 8%
• Transaminitis 8%
• Liver Enzymes Activity 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Human Study 100%
• Nonalcoholic Fatty Liver 100%
• Antilipemic Agent 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 10%
• Fatty Liver 10%
• Hyperlipidemia 10%
• Ethanol 5%
• Cardiovascular Disease 5%
• Liver Cell Carcinoma 5%
• Chronic Liver Disease 5%
• Liver Enzyme 5%
• Hypertransaminasemia 5%
• Metabolic Syndrome X 5%
• Liver Cirrhosis 5%
• Asymptomatic Disease 5%
• Fibric Acid Derivative 5%
• Fibrosis 5%